All stories by Sohini Das
I have no retirement or succession plans: Rajiv Bajaj
Rediff.com4 days agoBajaj Auto is gearing up to launch clean-energy vehicles including another motorcycle powered by compressed natural gas (CNG), showcase ethanol-powered motorcycles and three-wheelers next month, as well as launch a new Chetak platform early next year, as it closes in on hitting 100,000 monthly sales from clean-energy vehicles this festival season. In an interview with CNBC-TV18, Bajaj Auto managing director Rajiv Bajaj said these initiatives were part of the firm's broader goal to achieve monthly sales of 100,000 clean-energy vehicles this festival season.
'No question of bringing in an investor right now'
Rediff.com24 Aug 2024'We have got enough internal accruals, and we are able to do acquisitions on our own.'
'Bharat Serums and Vaccines portfolio can touch Rs 5K cr in 3-4 years'
Rediff.com9 Aug 2024'Mankind's experience, sharpness, and execution will make it happen. We are not going for short-term gains.'
TaMo looks to ace last-mile delivery with sub-600 kg SCV
Rediff.com7 Aug 2024Tata Motors, India's largest commercial vehicle manufacturer, is looking to launch a first-of-its-kind sub-600 kg small commercial vehicle, aiming to cater to the growing demand for efficient last-mile delivery solutions, an area currently witnessing a surge in interest from e-commerce giants. This new entrant is set to be positioned just below the marquee Tata Ace, which is popular across the country as "Chota Haathi".
Will Curvv Be An SUV Trend Setter?
Rediff.com31 Jul 2024'We will have multiple engine options -- electric vehicle and internal combustion engine in diesel and petrol.'
India's First Dengue Vaccine Likely To Be Ready By 2026
Rediff.com30 Jul 2024Dengue has become a major public health concern in India with 289,235 cases reported last year. This year there were 19,447 cases of dengue which resulted in 19 deaths till April 2024.
Diabetes Drug Linked To Vision Loss?
Rediff.com16 Jul 2024Study suggested that constant use of Semaglutide may be linked to development of a condition called non-arteritic ischemic optic neuropathy.
Bharat Biotech finally names ICMR as co-owner in Covaxin patent filings
Rediff.com25 Jun 2024After reports claimed that filings in patent offices in India, the US, and Europe did not mention ICMR or its scientists, but only BBIL and its scientists, the Hyderabad-based biotechnology (biotech) company clarified that in the "rush" to develop vaccines and file appropriate patents, BBIL had missed adding ICMR's name in the original filings.
Cleaner Fuels Driving One-Fifth Of PVs Sold In India
Rediff.com18 Jun 2024Auto manufacturers have focused on launching CNG variants of their popular models to meet consumer demand for vehicles with lower running costs.
'Second-gen promoters more open to selling out'
Rediff.com6 Jun 2024'There is not any negative connotation associated with it.'
'Depending on the product, the pricing pressure will always be there'
Rediff.com3 Jun 2024'That is a significant milestone for us and something we aspired for.'
New-Gen COVID Jabs Coming Soon...
Rediff.com28 May 2024India currently does not have any XBB 1.5 variant-based vaccines available.
Should Govt Continue Covid Vax Drive?
Rediff.com20 May 2024India has covered enough population with vaccine and infection, but protein vaccines should remain available on payment basis for elderly and those with comorbidities.
M&M shifts to high gear with Rs 37K cr investments
Rediff.com17 May 2024Automotive (auto) major Mahindra & Mahindra (M&M), which is readying to launch nine sport utility vehicles (internal combustion engine/ICE), seven Born Electric Vehicles (BEVs), and seven light commercial vehicles by 2030, has outlined an investment of Rs 27,000 crore in its auto business between 2024-25 (FY25) and 2026-27 (FY27). Over the next three years, the company will deploy Rs 37,000 crore, including its auto business, farm business (Rs 5,000 crore), and service business (Rs 5,000 crore).
Gut Health Key To Prevent Chronic Illnesses
Rediff.com24 Apr 2024Maintaining the balance of gut microbiota is important as an imbalance, also known as dysbiosis, can cause or aggravate different diseases, including but not limited to digestive problems such as inflammatory bowel syndrome, mental health issues like anxiety and depression and menstrual problems.
Zydus gets China nod for kidney disease drug
Rediff.com24 Apr 2024Ahmedabad-based Zydus Lifesciences said on Tuesday that a new drug application for its oral drug Desidustat used in treating anaemia in chronic kidney disease (CKD) patients had been accepted by the National Medical Products Administration of China (NMPA). In 2020, CMS International Development and Management Ltd, a wholly-owned subsidiary of China Medical System Holdings Ltd obtained an exclusive license for the product from Zydus. CKD involves a gradual loss of functioning of kidneys and eventually leads to kidney failure.
Nearly one in two luxury cars sold in March quarter was Mercedes Benz
Rediff.com12 Apr 2024Nearly one in two luxury cars sold in India in the first three months of 2024 was a Mercedes Benz, which achieved its best ever quarter (January-March), selling 5,412 units, up 15 per cent year-on-year (Y-o-Y) from 4,697 units in the previous year.
Why Drug Prices Won't Increase This Year
Rediff.com5 Apr 2024The government has been stringent with pricing changes. Prices of 651 essential medicines came down from April 1, 2023 by 6.73 per cent with the government capping ceiling prices of these drugs.
Why Hospital Stays Are Getting Shorter
Rediff.com3 Apr 2024'Every hospital now tracks length of stay closely.' 'More efficiency is brought into the system now.'
Indian pharma companies bank on 'mother brands' to boost revenue growth
Rediff.com28 Mar 2024Indian pharma companies are focussing on flagship products or mother brands under which they launch various new combinations to ensure robust revenue growth as well as therapy leadership. An analysis by market research firm Pharmarack showed how such flagship brands have posted strong growth CAGR in the last five years, with some even doubling sales. Sheetal Sapale, vice-president, commercial at Pharmarack, said, "Mother brands are analogous to an aggressive player who has put in a lot of effort during the prime years of life but now continues to silently nurture the brand family to collectively cross newer benchmarks of success."